Floatz logo

MDM2 INHIBITOR AMG-232

Non Hodgkin Lymphoma

Kartos Therapeutics, Inc.Small moleculePhase 1/2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
73/ 100

Competitive context

411 Active assets in the Non Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

MDM2 INHIBITOR AMG-232 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
Mantle Cell Lymphoma and Diffuse Large B Cell LymphomaDormant
CC
Indicative ·
41 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →